Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.…
Galderma-Chef laut Jefferies optimistisch hinsichtlich des Wachstums
Galderma Group (SWX: GALD) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 7,676 employees.
The shares were at 182.50 CHF on 20 November 2026, up 25.5% over 52 weeks. Its 52-week range is 136.30 CHF to 197.00 CHF: the price is 7.4% below the high and 33.9% above the low.
At a market capitalisation of 42.64B CHF, it trades at 63.1 times trailing earnings and 33.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 157% for GALD. It pays a dividend yielding 0.19% (it pays out 12% of its earnings), against a median of 2.04% among the dividend payers in that peer group.
Galderma Group reports return on equity of 7.5%, an operating margin of 19.1% and revenue up 27.7% year over year.
Its debt exceeds its cash by 1.88B USD, a debt-to-equity ratio of 0.34. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 17 analysts cover the stock, with an average rating of Buy; their mean price target of 210.64 CHF is 15.4% above the current price. The next earnings report is expected on 4 March 2027.